• Tsubasa Takizawa, Marenori Kojima, Shigeaki Suzuki, Takashi Osada, Satoshi Kitagawa, Jin Nakahara, Shinichi Takahashi, and Norihiro Suzuki.
• Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
• Medicine (Baltimore). 2017 Nov 1; 96 (46): e8757.

RationaleRecently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer.Patient ConcernsA 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks.DiagnosesOcular MG was confirmed by a positive serum anti-acetylcholine receptor antibody test.InterventionsTreatment with high-dose methylprednisolone pulse therapy was given, after insufficient treatment with pyridostigmine bromide and 10 mg/d prednisolone.OutcomesSymptoms resolved completely 12 days after high-dose methylprednisolone pulse therapy.LessonsIntravesical BCG could be listed as a novel drug that may induce a new onset of MG along with drugs such as D-penicillamine and immune checkpoint inhibitors.

18 keywords...

hide…